Search

Author/Creator Small, Eric J.

1. Accelerating cancer clinical trial recruitment through a financial reimbursement program integrated with patient navigation: an interrupted time series analysis. (December 2021)

Authors:
Borno, Hala T.; Lin, Tracy Kuo; Zhang, Sylvia; Skafel, Andrea; Lalanne, Alyssa; Dornsife, Dana; Johnson, Robert; Spicer, Darcy; Small, Eric J.; Rhoads, Kim F.
Journal:
Journal of cancer policy
Issue:
Volume 30(2021)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. An improved CTC isolation scheme for pairing with downstream genomics: Demonstrating clinical utility in metastatic prostate, lung and pancreatic cancer. Issue 1 (28th September 2016)

Authors:
Premasekharan, Gayatri; Gilbert, Elizabeth; Okimoto, Ross A.; Hamirani, Ashiya; Lindquist, Karla J.; Ngo, Vy T.; Roy, Ritu; Hough, Jeffrey; Edwards, Matthew; Paz, Rosa; Foye, Adam; Sood, Riddhi; Copren, Kirsten A.; Gubens, Matthew; Small, Eric J.; Bivona, Trever G.; Collisson, Eric A.; Friedlande...
Journal:
Cancer letters
Issue:
Volume 380:Issue 1(2016)
Page Start:
144
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Baseline Testosterone Levels in Men with Clinically Localized High-Risk Prostate Cancer Treated with Radical Prostatectomy with or without Neoadjuvant Chemohormonal Therapy (Alliance). Issue 2 (29th August 2021)

Authors:
Eastham, James A.; Heller, Glenn; Hillman, David W.; Hahn, Olwen M.; Parsons, J. Kellogg; Mohler, James L.; Small, Eric J.; Morris, Michael
Journal:
Journal of urology
Issue:
Volume 206:Issue 2(2021)
Page Start:
319
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. Bevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castration‐resistant prostate cancer treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance). Issue 7 (21st November 2014)

Authors:
Patel, Jai N.; Jiang, Chen; Hertz, Daniel L.; Mulkey, Flora A.; Owzar, Kouros; Halabi, Susan; Ratain, Mark J.; Friedman, Paula N.; Small, Eric J.; Carducci, Michael A.; Mahoney, John F.; Kelley, Michael J.; Morris, Michael J.; Kelly, William K.; McLeod, Howard L.
Journal:
Cancer
Issue:
Volume 121:Issue 7(2015)
Page Start:
1025
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update. (May 2018)

Authors:
Choueiri, Toni K.; Hessel, Colin; Halabi, Susan; Sanford, Ben; Michaelson, M. Dror; Hahn, Olwen; Walsh, Meghara; Olencki, Thomas; Picus, Joel; Small, Eric J.; Dakhil, Shaker; Feldman, Darren R.; Mangeshkar, Milan; Scheffold, Christian; George, Daniel; Morris, Michael J.
Journal:
European journal of cancer
Issue:
Volume 94(2018)
Page Start:
115
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. Cabozantinib Versus Sunitinib for Untreated Patients with Advanced Renal Cell Carcinoma of Intermediate or Poor Risk: Subgroup Analysis of the Alliance A031203 CABOSUN trial. (9th August 2019)

Authors:
George, Daniel J.; Hessel, Colin; Halabi, Susan; Michaelson, M. Dror; Hahn, Olwen; Walsh, Meghara; Picus, Joel; Small, Eric J.; Dakhil, Shaker; Feldman, Darren R.; Mangeshkar, Milan; Scheffold, Christian; Morris, Michael J.; Choueiri, Toni K.
Journal:
Oncologist
Issue:
Volume 24:Number 11(2019)
Page Start:
1497
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. Corrigendum to 'Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update' [Eur J Cancer 94 (May 2018) 115–125]. (November 2018)

Authors:
Choueiri, Toni K.; Hessel, Colin; Halabi, Susan; Sanford, Ben; Michaelson, M. Dror; Hahn, Olwen; Walsh, Meghara; Olencki, Thomas; Picus, Joel; Small, Eric J.; Dakhil, Shaker; Feldman, Darren R.; Mangeshkar, Milan; Scheffold, Christian; George, Daniel; Morris, Michael J.
Journal:
European journal of cancer
Issue:
Volume 103(2018)
Page Start:
287
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

9. Differential treatment outcomes in BRCA1/2‐, CDK12‐, and ATM‐mutated metastatic castration‐resistant prostate cancer. Issue 12 (10th March 2021)

Authors:
Kwon, Daniel H.; Chou, Jonathan; Yip, Steven M.; Reimers, Melissa A.; Zhang, Li; Wright, Francis; Dhawan, Mallika S.; Borno, Hala T.; Desai, Arpita; Aggarwal, Rahul R.; Wyatt, Alexander W.; Small, Eric J.; Alva, Ajjai S.; Chi, Kim N.; Feng, Felix Y.; Koshkin, Vadim S.
Journal:
Cancer
Issue:
Volume 127:Issue 12(2021)
Page Start:
1965
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗